In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Inozyme Pharma (INZY – Research Report). The company’s shares closed last Friday at $2.00. Discover ...

David Lebowitz, an analyst from Citi, maintained the Buy rating on Alnylam Pharma (ALNY – Research Report). The associated price target is $340.00. Discover outperforming stocks and invest ...

COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones.

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Forbes does not accept payment for placement on lists.

Dainippon Sumitomo Pharma (DSP), and Evotec. Those deals had already made Exscientia one of the most well-funded players in the AI drug discovery category even before it closed a $510 million ...

SINGAPORE: Singapore and South Korea launched a logo to be used in events celebrating the 50th anniversary of diplomatic relations between the two countries. The logo, unveiled on Monday (Jan 13 ...

Repurchase of Common & Preferred Stk. Repurchase of Common & Preferred Stk.

COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones.

Nanomembranes are a type of nanomaterial with ultra-thin structures at the nanometer scale and lateral dimensions that can extend to millimeters or even centimeters. These membranes are strong enough ...